Syngene International IPO Details: Price, Dates & Financials

Pre-issue shareholding: 200,000,000 shares. Post-issue shareholding: 200,000,000 shares.

Syngene International IPO is a Offer For Sale issue. Issue type: Bookbuilding IPO. Face value is ₹10.

The UPI mandate for Syngene International IPO needs to be accepted by 29 Jul 2015. Approve the mandate request in your UPI app before the deadline, otherwise your bid may be rejected.

The Red Herring Prospectus (RHP) of Syngene International IPO is available on the website of the lead manager and the stock exchange (NSE & BSE) — see the lead manager links on the main page.

The DRHP is the initial offer document filed for regulatory review, while the RHP includes updated disclosures, final issue details, and the price band (when announced). Comparing both documents helps investors identify changes in the Syngene International IPO's financial information, risks, and offer terms before investing in the Syngene International IPO. Reviewing both documents provides a clearer understanding of the Syngene International IPO before making an investment decision.

The DRHP and RHP of the Syngene International IPO disclose potential risks related to the company's business, financial performance, legal matters, and industry conditions. Reviewing these documents helps investors identify potential concerns about the Syngene International IPO, evaluate the Syngene International IPO's risk factors, and make a more informed decision before investing in the Syngene International IPO.